natgillin/translations-raw huggingface dataset:
Skin reaction, Jessner's lymphocytic infiltration, Palmarplantar erythrodysaesthesia syndrome, Haemorrhage subcutaneous, Livedo reticularis, Skin induration, Papule, Photosensitivity reaction, Seborrhoea, Cold sweat, Skin disorder NOS, Erythrosis, Skin ulcer, Nail disorder 
Redki kožna reakcija, limfocitna infiltracija Jessner, sindrom palmarnoplantarne eritrodisestezije, podkožne krvavitve, livedo retikularis, zatrdlina kože, papule, fotosenzitivna reakcija, seboreja, hladen znoj, bolezni kože NOS, eritroza, kožna razjeda, bolezni nohtov
When VELCADE is given in combination with other medicinal products, the Summary of Product Characteristics of these other medicinal products must be consulted prior to initiation of treatment with VELCADE. 
Kadar se zdravilo VELCADE uporablja v kombinaciji z drugimi zdravili je treba prebrati Povzetke glavnih značilnosti teh zdravil pred začetkom zdravljenja z zdravilom VELCADE.
• low numbers of red or white blood cells 
• imate majhno število rdečih (eritrocitov) ali belih (levkocitov) krvnih celic,
#, Hypersensitivity* 
Pogosti preobčutljivost*
In a few cases, patients who have had hepatitis B might have a repeated attack of hepatitis, which can be fatal. 
Pri bolnikih, ki so imeli hepatitis B,
• Injection site or injection device related disorders 
• zapleti na mestu injiciranja ali zapleti, povezani z uporabo katetra
Uncommon Hepatitis B, Infection*, Bronchopneumonia 
Občasni okužba z virusom hepatitisa B*, bronhopnevmonija
Herpes zoster (inc disseminated & ophthalmic), Pneumonia*, Herpes simplex*, Fungal infection* 
Pogosti herpes zoster (vključno z diseminiranim in očesnim), pljučnica*, herpes simplex*, glivična okužba*
TTP, days [95% CI] 1 year survival, 
TTP, dnevi ([95% CI]) 1-letno preživetje,% [95% CI] Najboljši odziv (%)
You might receive up to 6 cycles (24 weeks). 
Lahko boste do prejeli 6 krogov zdravljenja (24 tednov).
Very Common Hair disorder* Common Pruritus*, Dermatitis*, Rash* 
Zelo pogosti bolezni las* Pogosti srbenje*, dermatitis*, izpuščaj*
There have been isolated cases of QT-interval prolongation in clinical studies, causality has not been established. 
Vzroka za podaljšanje QT intervala niso ugotovili.
• Inflammation of a vein, blood clots in your veins and lungs 
• vnetje ven, krvni strdki v venah in pljučih
The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the VELCADE monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the VELCADE plus pegylated liposomal doxorubicin combination therapy patients. 
Za bolnike, zdravljene samo z zdravilom VELCADE je bilo mediano OS 30,8 mesecev (95% CI; 25,2-36,5 mesecev), za bolnike, zdravljene z zdravilom VELCADE v kombinaciji s pegiliranim liposomskim doksorubicinom pa 33,0 mesecev (95% CI; 28,9-37,1 meseca).
Early and regular monitoring for symptoms of treatment-emergent neuropathy with neurological evaluation should be considered in patients receiving VELCADE in combination with medicinal products known to be associated with neuropathy (e.g. thalidomide) and appropriate dose reduction or treatment discontinuation should be considered. 
Pri bolnikih, ki prejemajo zdravilo VELCADE v kombinaciji z zdravili, ki so povezana s pojavom nevropatije (npr. talidomid), je potrebno zgodnje in redno spremljanje pojava simptomov (z zdravljenjem povezane) nevropatije, opraviti nevrološko oceno ter ustrezno zmanjšati odmerek ali razmisliti o ukinitvi zdravljenja.
In studies in patients with relapsed multiple myeloma treated with VELCADE and in patients with previously untreated MCL treated with VELCADE in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP), one of the most common haematologic toxicity was transient thrombocytopenia. 
V študijah zdravljenja z zdravilom VELCADE pri bolnikih s ponovitvijo diseminiranega plazmocitoma in pri bolnikih z nezdravljenim MCL, v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom in prednizonom (VcR-CAP), je bil najpogostejši toksični učinek na hematološki sistem prehodna trombocitopenija.
VELCADE is used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable. 
Zdravilo VELCADE se uporablja za zdravljenje limfoma plaščnih celic (redka oblika raka, ki prizadene bezgavke) pri bolnikih, starih 18 let in več, v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom in prednizonom, pri bolnikih, pri katerih bolezni še nismo zdravili in pri katerih presaditev krvotvornih matičnih celic ni primerna.
Patient demographic and baseline disease charateristics were similar between the treatment groups. 
Bolniki v obeh skupinah so imeli podobne demografske in bolezenske značilnosti.
Hypermagnesaemia*, Acidosis, Electrolyte imbalance*, Fluid overload, Hypochloraemia*, Hypovolaemia, Hyperchloraemia*, Hyperphosphataemia*, Metabolic disorder, Vitamin B complex deficiency, Vitamin B12 deficiency, Gout, Increased appetite, Alcohol intolerance 
Redki hipermagneziemija*, acidoza, motnje ravnovesja elektrolitov*, čezmerno nabiranje tekočine, hipokloremija*, hipovolemija, hiperkloremija*, hiperfosfatemija*, presnovne motnje, pomanjkanje vitaminov B kompleksa, pomanjkanje vitamina B12, protin, zvečan apetit, neprenašanje alkohola
Marketing Authorisation Holder JANSSEN-CILAG INTERNATIONAL NV Turnhoutseweg 30 
Imetnik dovoljenja za promet JANSSEN-CILAG INTERNATIONAL NV Turnhoutseweg 30
Be sure that the correct dose is being given for the subcutaneous route of administration (2.5 mg/ml). 
Na viali preverite koncentracijo, da zagotovite pravilni odmerek za subkutano dajanje zdravila (2,5 mg/ml).
General precautions 
Spošni previdnostni ukrepi
• Sore mouth or lip, throat pain 
• vnetje ust ali ustnic, bolečina v žrelu
• Bloody stools, or bleeding from mucosal membranes, e.g., mouth, vagina 
• krvavo blato, krvavitve iz sluznic, npr. v ustih, nožnici
Potentially immunocomplex-mediated reactions 
Reakcije, povzročene z imunskimi kompleksi
If local injection site reactions occur following VELCADE subcutaneous injection, either a less concentrated VELCADE solution (VELCADE 3.5 mg to be reconstituted to 1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended. 
Če se po subkutanem injiciranju zdravila VELCADE na mestu injiciranja pojavijo lokalne reakcije, se priporoča, da subkutano injicirate manj koncentrirano raztopino zdravila VELCADE (1 mg/ml namesto 2,5 mg/ml) ali pa preidete na intravensko dajanje zdravila.
Day 1, 2, 3, 4 Day 8, 9, 10, 11Cycles 2 to 4 
Dx 40 mg dan 1, 2, 3, 4 dan 8, 9, 10, 11krogi 2 do 4
In trials in which VELCADE was administered as induction treatment in combination with dexamethasone (study IFM-2005-01), and dexamethasone-thalidomide (study MMY-3010), the incidence of peripheral neuropathy in the combination regimens is presented in the table below: 
Pojavnost periferne nevropatije v preskušanjih zdravila VELCADE pri uvajalnem zdravljenju v kombinaciji z deksametazonom (študija IFM-2005-01) ter deksametazonom in talidomidom (študija MMY-3010) je navedena v spodnji preglednici:
* Based on posology modifications in Phase II and III multiple myeloma studies and post-marketing experience. 
na osnovi prilagoditev odmerjanja v študijah faze II in III pri bolnikih z diseminiranim plazmocitomom in izkušenj v obdobju trženja.
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Vc=VELCADE; VcTDx=VELCADE, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response; OR=odds ratio * Primary endpoint 
CI = interval zaupanja; CR = popoln odgovor; nCR = skoraj popoln odgovor; ITT = populacija, ki so jo nameravali zdraviti; RR = stopnja odgovora; Vc = VELCADE; VcTDx = VELCADE, talidomid, deksametazon; TDx = talidomid, deksametazon; PR = delni odgovor; OR = razmerje verjetnosti;
A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC reduction of 45% based on data from 6 patients. 
Študija medsebojnega delovanja zdravil, ki je ocenjevala učinek rifampicina, močnega induktorja encima CYP3A4, na farmakokinetiko bortezomiba (danega intravensko), je na osnovi podatkov 6 bolnikov pokazala povprečno zmanjšanje AUC bortezomiba za 45%.
Hepatitis B Virus (HBV) reactivation and infection When rituximab is used in combination with VELCADE, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment. 
Reaktivacija in okužba z virusom hepatitisa B (HBV) Pri bolnikih s tveganjem za okužbo s HBV je treba pred uporabo rituksimaba v kombinaciji z zdravilom VELCADE vedno opraviti presejalni test na HBV. Prenašalce virusa hepatitisa B in bolnike, ki so že bili okuženi z virusom hepatitisa B, je treba med zdravljenjem in v nadaljevanju zdravljenja z rituksimabom v kombinaciji z zdravilom VELCADE skrbno spremljati glede kliničnih in laboratorijskih znakov aktivne okužbe s HBV.
CR+nCR+PR % (95% CI) *RR (Post-transplant) CR+nCR 
CR+nCR+PR% (95% CI) *RR (po presaditvi) CR+nCR
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. 
Če se je ne porabi takoj, je za čas in pogoje shranjevanja zdravila po rekonstituciji odgovoren uporabnik.
RR (Post-induction) *CR+nCR 
RR (po uvedbi) *CR+nCR
Patients in the VcTDx group received six 4-week cycles, each consisting of VELCADE (1.3 mg/m administered twice weekly days 1, 4, 8, and 11, followed by a 17-day rest period from day 12 to day 28), dexamethasone (40 mg administered orally on days 1 to 4 and days 8 to 11), and thalidomide (administered orally at 50 mg daily on days 1-14, increased to 100 mg on days 15-28 and thereafter to 200 mg daily). 
V vsakem krogu so prejeli zdravilo VELCADE (1.3 mg/m2 dvakrat na teden na 1., 4., 8., in 11. dan, ki mu sledi 17-dnevni premor od 12. do 28. dne), deksametazon (40 mg peroralno na 1. do 4. dan in 8. do 11. dan) in talidomid (50 mg na dan peroralno na 1. do 14. dan, povečan odmerek 100 mg na 15. do 28. dan in potem povečan odmerek 200 mg na dan).
Also included are adverse drug reactions identified in the VcR-CAP arm that were considered by investigators to have at least a possible or probable causal relationship to VELCADE based on historical data in the multiple myeloma studies. 
Vključeni so tudi neželeni učinki, ugotovljeni v skupini VcR-CAP, ki so na osnovi podatkov študij diseminiranega plazmocitoma in po mnenju raziskovalcev najmanj verjetno ali možno povezani z uporabo zdravila VELCADE.
• symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion, 
• imate simptome sindroma razpada tumorja kot so mišični krči, šibkost mišic, zmedenost, izguba ali motnje vida ali težko dihate,
Clinical efficacy in previously untreated mantle cell lymphoma (MCL) Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV). 
V randomizirani, odprti študiji faze III, LYM-3002, so pri odraslih bolnikih s predhodno nezdravljenim MCL (stopnje II, III ali IV) primerjali učinkovitost in varnost zdravila VELCADE v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom, vinkristinom in prednizonom (VcR-CAP; n = 243) z zdravljenjem z rituksimabom, ciklofosfamidom, doksorubicinom, vinkristinom in prednizonom (R-CHOP; n = 244).
VELCADE 3.5 mg reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection. 
VELCADE 3,5 mg rekonstituirano raztopino dajte naenkrat v obliki 3-5 sekund trajajoče bolusne intravenske injekcije preko perifernega ali osrednjega intravenskega katetra, čemur naj sledi izpiranje katetra z 9 mg/ml (0,9%) raztopino natrijevega klorida za injiciranje.
There is no evidence to suggest that dose adjustments are necessary in patients over 65 years of age with multiple myeloma or with mantle cell lymphoma. 
Dokazov, ki bi potrdili, da je pri bolnikih z diseminiranim plazmocitomom ali limfomom plaščnih celic, starejših od 65 let potrebna prilagoditev odmerka, ni.
bleeding of the eye 
• krvavitve iz nosu
VcR-CAP=VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy 
VcR-CAP = VELCADE, rituksimab, ciklofosfamid, doksorubicin in prednizon; R-CHOP = rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon; PN = periferna nevropatija Periferna nevropatija vključuje priporočene termine: periferna senzorična nevropatija, periferna nevropatija, periferna motorična nevropatija in periferna senzomotorična nevropatija.
• Joint or muscle stiffness, sense of heaviness, pain in your groin 
• okorelost sklepov ali mišic, občutek teže, bolečine v dimljah
• Infections, including pneumonia, respiratory infections, bronchitis, fungal infections, coughing with phlegm, flu like illness 
• okužbe, vključno s pljučnico, okužba dihal, bronhitis, glivične okužbe, produktiven kašelj, gripi podobna bolezen
• Platelet counts should be ≥ 100,000 cells/μL and the absolute neutrophils count (ANC) should be ≥ 1,500 cells/μL 
• Število trombocitov mora biti ≥ 100.000 celic/μl in celokupno število nevtrofilcev
Once the symptoms of the toxicity have resolved, VELCADE treatment may be re-initiated at a 25% reduced dose (1.3 mg/m2 reduced to 1.0 mg/m2; 1.0 mg/m2 reduced to 0.7 mg/m2). 
Ko znaki toksičnosti minejo, lahko zdravljenje z zdravilom VELCADE ponovno uvedete, vendar s 25% manjšim odmerkom (1,3 mg/m2 zmanjšano na 1,0 mg/m
CR+nCR+ PR+MR 
CR+ nCR + PR
Time to next therapy Events n (%) Median (95% CI) 
Čas do naslednjega zdravljenja dogodki n (%) mediana a (95% CI)
#, Eye inflammation*, Diplopia, Dry eye*, Eye irritation*, Eye pain, Lacrimation increased, Eye discharge 
#, vnetje očesa*, diplopija, suhe oči*, draženje očesa*, bolečina v očesu, povečano solzenje, izcedek iz očesa
• Blood clots in your lungs 
• krvni strdki v pljučih
Both in patients who were refractory to their last prior therapy and those who were not refractory, overall survival was significantly longer and response rate was significantly higher on the VELCADE arm. 
Tako pri bolnikih s plazmocitomom, odpornim na zdravljenje, po prejšnji vrsti zdravljenja, kot pri tistih, ki so se odzvali na zdravljenje, je bilo celokupno preživetje v skupini, ki je prejemala VELCADE, statistično značilno daljše in odziv na zdravljenje je bil statistično značilno boljši.
The primary efficacy endpoint was TTP while the secondary efficacy endpoints were OS and ORR (CR+PR), using the European Group for Blood and Marrow Transplantation (EBMT) criteria. 
Po kriterijih Evropske skupine za transplantacijo kostnega mozga (EBMT - European Group for Blood and Marrow Transplantation) je bil primarni opazovani dogodek glede učinkovitosti TTP, sekundarna opazovana dogodka glede učinkovitosti pa OS in ORR (CR+PR).
An open label, randomised, Phase III non-inferiority study compared the efficacy and safety of the subcutaneous administration of VELCADE versus the intravenous administration. 
V odprti, randomizirani, študiji faze III na dveh enakovrednih skupinah so primerjali učinkovitost in varnost subkutanega in intravenskega dajanja zdravila VELCADE.
#, Dermatitis*, Hair disorder*, Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*, Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer Acne*, Blister*, Pigmentation disorder* 
#, dermatitis*, bolezni las*, petehije, ehimoze, spremembe na koži, purpura, kožna masa*, luskavica, hiperhidroza, nočno znojenje, dekubitusna razjeda
24.0 mo 
24,0 mesecev
Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors. 
Presnovka, ki nastaneta po odcepitvi bora ne delujeta kot zaviralca 26S proteasoma.
In an exploratory efficacy analysis, a 67.3% response rate (including a 28.6% CR rate) as measured by hematologic response (M-protein) was reported in 49 evaluable patients treated with the maximum allowed doses of 1.6 mg/m2 weekly and 1.3 mg/m2 twice-weekly. 
Pri analizi učinkovitosti, merjene s hematološkim odzivom (M-protein), pri 49 bolnikih, pri katerih je bila mogoča ocena in so prejemali največje dovoljene odmerke 1,6 mg/m2 na teden in 1,3 mg/m2 dvakrat na teden, je bila stopnja odziva 67,3% (vključno z deležem CR 28,6%).
Week Vc (1.3 mg/m 
Teden Vc (1,3 mg/m dan 1, 4
• Difficulty or problems in sleeping, sweating, anxiety, mood swings, depressed mood, 
• težave s spanjem, znojenje, tesnoba, nihanje razpoloženja, depresivno razpoloženje, nemir ali vznemirjenost, spremembe v vašem duševnem stanju, dezorientiranost
VELCADE might cause tiredness, dizziness, fainting, or blurred vision. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo VELCADE lahko povzroči utrujenost, omotičnost, omedlevico ali zamegljen vid.
VELCADE contains the active substance bortezomib, a so-called ‘proteasome inhibitor'. 
Zdravilo VELCADE vsebuje učinkovino bortezomib, ki je zaviralec proteasomov.
The reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection. 
Rekonstituirano raztopino dajte naenkrat v obliki 3-5 sekund trajajoče bolusne intravenske injekcije preko perifernega ali osrednjega intravenskega katetra, čemur naj sledi izpiranje katetra z 9 mg/ml (0,9%) raztopino natrijevega klorida za injiciranje.
In B-ALL patients with relapse within 18 months of diagnosis (n = 27) the CR rate was 67% (95% CI: 46, 84); the 4-month event free survival rate was 44% (95% CI: 26, 62). 
Pri bolnikih z Bcelično ALL in relapsom v manj kot 18 mesecih po diagnozi (n = 27) je bil delež popolnih odgovorov 67% (95% CI: 46, 84) in delež 4-mesečnega preživetja bolnikov brez dogodkov 44% (95% CI: 26, 62).
• Problems with blood clotting 
• motnje v strjevanju krvi
Neutrophils were lowest at Day 11 of each cycle of VELCADE treatment and typically recovered to baseline by the next cycle. 
Število nevtrofilcev je bilo najmanjše 11. dan vsakega cikla zdravljenja z zdravilom VELCADE in se je do naslednjega kroga zdravljenja običajno povrnilo na začetno vrednost.
Each carton of VELCADE 3.5 mg powder for solution for injection contains a glass 10 ml vial with a royal blue cap, in a transparent blister pack. 
Ena škatla zdravila VELCADE 3,5 mg prašek za raztopino za injiciranje vsebuje stekleno 10 ml vialo s pokrovčkom modre barve v prozorni zavarjeni vrečki.
• Respiratory infections, bronchitis, coughing with phlegm, flu like illness 
• okužbe dihal, bronhitis, produktiven kašelj, gripi podobna bolezen
tiredness, fainting - coughing and breathing difficulties or tightness in the chest. 
omedlevica - težave s kašljem in dihanjem ali tiščanje v prsih
The resulting solution is then either injected into a vein or under the skin. 
Nastalo raztopino se nato injicira v veno ali v podkožje.
In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 17 patients. 
V študiji medsebojnega delovanja zdravil, ki je ocenjevala učinek omeprazola, močnega inhibitorja encima CYP2C19, na farmakokinetiko bortezomiba (danega intravensko), na osnovi podatkov 17 bolnikov, ni bilo pomembnega vpliva na farmakokinetiko bortezomiba.
In patients developing PRES, VELCADE should be discontinued. 
Če se pri bolniku razvije PML, je treba zdravljenje z zdravilom VELCADE prekiniti.
Table 7: Adverse reactions in patients with Multiple Myeloma treated with VELCADE in clinical trials, and all post-marketing adverse reactions regardless of indication System Organ Class 
Preglednica 7: Neželeni učinki pri bolnikih z diseminiranim plazmocitomom, zdravljenih z zdravilom VELCADE v kliničnih preskušanjih in v obdobju trženja, neodvisno od indikacije
As a result of a pre-planned interim analysis, the dexamethasone arm was halted at the recommendation of the data monitoring committee and all patients randomised to dexamethasone were then offered VELCADE, regardless of disease status. 
Kot rezultat predhodno načrtovane vmesne analize, so del preskušanja, v katerem so bolniki dobivali deksametazon zaključili v skladu s priporočilom komisije, ki je spremljala podatke.
The primary efficacy endpoints of the study were post-induction and post-transplant response rates (CR+nCR). 
Primarna ocena učinkivitosti je bila stopnja odgovora po uvedbi zdravljenja in po presaditvi (CR+nCR).
Patients in the VcDx group received four 21 day cycles, each consisting of VELCADE (1.3 mg/m2 administered intravenously twice weekly on days 1, 4, 8, and 11), and oral dexamethasone (40 mg/day on days 1 to 4 and days 9 to 12, in Cycles 1 and 2, and on days 1 to 4 in Cycles 3 and 4). 
V vsakem krogu so prejeli zdravilo VELCADE (1,3 mg/m2 intravensko dvakrat na teden na 1., 4., 8. in 11. dan) in deksametazon (40 mg/dan, peroralno, 1. do 4. in 9. do 12. dan v 1. in 2. krogu in 1. do 4. dan v 3. in 4. krogu).
*RR (Post-induction) CR+nCR 
*RR (po uvedbi) CR+nCR
Atrial flutter, Myocardial infarction*, Atrioventricular block*, Cardiovascular disorder (inc cardiogenic shock), Torsade de pointes, Angina unstable, Cardiac valve disorders*, Coronary artery insufficiency, Sinus arrest 
Redki atrijska undulacija, miokardni infarkt*, atrioventrikularni blok*, srčno-žilne bolezni (vključno s kardiogenim šokom), Torsade de pointes, nestabilna angina pektoris, bolezni srčnih zaklopk*, insuficienca koronarnih arterij, sinusni zastoj
After reconstitution, each ml solution contains 2.5 mg bortezomib. 
Po rekonstituciji, vsak ml raztopine vsebuje 2,5 mg bortezomiba.
Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease. 
Ocena razmerja tveganja na osnovi Coxovega modela, stratificirani z IPI tveganjem in stopnjo bolezni.
Four treatment cycles of this combination therapy are administered. 
Bolnik prejme štiri kroge kombiniranega zdravljenja.
222 patients with relapsed/refractory multiple myeloma, who were randomised in a 2:1 ratio to receive 1.3 mg/m2 of VELCADE by either the subcutaneous or intravenous route for 8 cycles. 
V študijo je bilo vključenih 222 bolnikov z relapsom/diseminiranim plazmocitomom, odpornim na zdravljenje, randomiziranih 2:1 na zdravilo VELCADE, z odmerkom1,3 mg/m2 telesne površine subkutano ali intravensko 8 krogov zdravljenja.
p-value is for the non-inferiority hypothesis that the SC arm retains at least 60% of the response rate in the IV arm. 222 subjects were enrolled into the study; 221 subjects were treated with VELCADE Hazards ratio estimate is based on a Cox model adjusted for stratification factors: ISS staging and number of prior lines. 
V študijo je bilo vključenih 222 preiskovancev; 221 preiskovancev se je zdravilo z zdravilom VELCADE Ocena stopnje tveganja temelji na modelu po Cox-u, prilagojen na osnovi stratifikacijaskih faktorjev: ISS razvrstitvi in številu predhodnih zdravljenj.
• Loss of conciousness 
• izguba zavesti
The protocol allowed patients to receive dexamethasone if they had had a less than optimal response to VELCADE alone. 
V skladu s protokolom so bolniki lahko prejeli deksametazon, če ni bilo pričakovanega odziva na zdravljenje z zdravilom VELCADE v monoterapiji.
It is recommended that patients receive 2 cycles of VELCADE following a confirmation of a complete response. 
Priporočamo, da bolniki po potrjenem popolnem odgovoru prejmejo še 2 kroga zdravljenja z zdravilom VELCADE.